Company: DNLI
Filing Date: 2025-12-09
Form Type: 424B5
Source: 0001628280-25-056085
Chunk: 7

Company: Denali Therapeutics Inc.
Filing Date: 2025-12-09
Form: 424B5
Chunk 7
---
AA) for Pompe disease, and other preclinical programs, including DNL921 (ATV:Abeta) for Alzheimer’s disease. Our small molecule clinical development portfolio includes BIIB122/DNL151 (LRRK2 inhibitor, partnered with Biogen) for Parkinson’s disease and eclitasertib (SAR443122 RIPK1 Inhibitor, partnered with Sanofi) for ulcerative colitis. We believe the combination of a clinically validated delivery platform and a maturing therapeutic portfolio will position us for long-term success in our goal to deliver barrier-crossing, targeted, and effective medicines.

#### Company Information
We were incorporated in Delaware in October 2013. Our principal executive offices are located at 161 Oyster Point Blvd, South San Francisco, CA and our telephone number at that address is (650) 866-8547. We maintain an Internet website at the following address: www.denalitherapeutics.com. The information on, or that can be accessed through, our website does not constitute part of this prospectus supplement or the accompanying prospectus, and you should not rely on any such information in making an investment decision.

<div align='center'>S-4</div>

| THE OFFERING                                          |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Common stock offered by us                            |     | shares. We have also granted the underwriters a 30-day option to purchase up to              additional shares.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Pre-funded warrants offered by us                     |     | We are also offering, in lieu of common stock, to certain investors, pre-funded warrants to purchase                shares of common stock. The purchase price of each pre-funded warrant equals the price per share at which shares of common stock are being sold to the public in this offering, minus $0.01, which is the exercise price of each pre-funded warrant. The pre-funded warrants do not expire, and each pre-funded warrant will be exercisable at any time after the date of issuance, subject to an ownership limitation. See “Description of Pre-Funded Warrants.” This preliminary prospectus supplement also relates to the offering of the shares of common stock issuable upon the exercise of such pre-funded warrants. |
| Common stock to be outstanding following the offering |     | shares (or               shares if the underwriters exercise their option to purchase additional shares in full), in each case assuming no exercise of any pre-funded warrants offered and sold by us.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Use of proceeds                                       |